[ad_1]
Epclone ® a drug of the pharmaceutical group Gilead Sciences for the pan-genotypic and panfibrotic treatment of hepatitis C virus, achieved cure rates of 98% in just twelve weeks with a single tablet per day
June 29, 2018 – Anvisa has just published the approval of Epclusa ® (sofosbuvir 400mg / velpatasvir 100mg), a drug of Gilead Sciences for pangenotypic treatment (genotype 1 at 6) and panfibrotic of the hepatitis C virus in adults. Epclusa ® offers 98% cure rates in just 12 weeks of treatment for all patient profiles
"Anvisa's approval of Epclusa® is still another major step in the treatment of hepatitis C in Brazil, mainly for the possibility of curing all genotypes of the virus and all patients in the different phases of the disease (cases of light fibrosis to cirrhotic and transplanted ) in a simple and effective way with a single tablet a day for only 12 weeks, says Dr. Anita Campos, medical director of Gilead
The effectiveness of Epclusa® has been evaluated in five studies involving more than 1,200 patients with cure rates, also called sustained virological response (98%) .The studies also showed results in patients who were in different situations, such as those who already have have been treated, people with advanced liver disease, such as cirrhosis;
HCV
Hepatitis C is an infection caused by the hepatitis C virus (HCV) that has at least six types of infection with the virus Hepatitis C (HCV) before and after liver transplantation. (genotypes) and which preferentially affects the liver, causing inflammation that leads to scarring (hepatic fibrosis) and which, with time and without treatment, can lead to cirrhosis and liver cancer. In addition to the liver, other organs can also be affected.
Chronic hepatitis C affects approximately 71 million people worldwide. In Brazil, there are approximately 657,000 patients with the disease. About 155,000 were diagnosed between 1999 and 2016 and there are indications that 502,000 people are still missing to be diagnosed. During this period, 110,000 treatments were performed, of which 57,000 only between 2015 and 2017. Between 2000 and 2015, 46,314 deaths related to hepatitis C were identified; of four deaths due to viral hepatitis in Brazil, three (75.6%) are due to HCV. The fact is that a large part ignores his diagnosis and few are aware of the transmission or treatment of the disease.
"The disease is asymptomatic in 80% of cases and makes it a serious public health problem, which may take decades to show signs, usually manifesting itself at an advanced stage of liver injury or with badociated images, "Dr. Anita concludes.
HCV is transmitted through contact with infected blood, and the primary means of transmission is inadequate sterilization of medical, dental, and other equipment, needle sharing, and syringes (such as in the use of illicit drugs), unsafe bad and mother to child transmission, and people who received blood transfusions prior to 1993 may also have contracted. Infection
Hepatitis C is the leading cause of cirrhosis, liver cancer and liver transplantation in the world.In addition to liver-related complications, it can trigger a true systemic disease. Studies have shown that the hepatitis C virus increases the risk of developing other diseases such as type 2 diabetes and lymphoma, for example
About Gilead Sciences
Gilead Sciences biopharmaceutical research, development and commercialization of innovative therapies for the prevention, treatment and cure of life-threatening diseases such as HIV / AIDS, viral hepatitis, among others. Gilead was responsible for great achievements in health and quality of life by offering the first single antiretroviral pill regimen for the treatment of HIV / AIDS, and by revolutionizing the treatment of hepatitis C with the first drug that introduced
Present in Brazil since 2013 and headquartered in São Paulo, Gilead is present in more than 35 countries and is headquartered in Foster City, California, USA.
Fn ] Background RP
Source link
